{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:28:21Z","timestamp":1744417701867,"version":"3.40.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00699"],"award-info":[{"award-number":["PI22\/00699"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PI22\/00699"],"award-info":[{"award-number":["PI22\/00699"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ymgme.2024.108538","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T06:59:59Z","timestamp":1721199599000},"page":"108538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["HepG2 PMM2-CDG knockout model: A versatile platform for variant and therapeutic evaluation"],"prefix":"10.1016","volume":"143","author":[{"given":"Alicia","family":"Vilas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Briso-Montiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Segovia-Falquina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Mart\u00edn-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Soriano-Sexto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Ruiz-Mont\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"G\u00e1mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ymgme.2024.108538_bb0005","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/1098-1004(200011)16:5<386::AID-HUMU2>3.0.CO;2-Y","article-title":"Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia)","volume":"16","author":"Matthijs","year":"2000","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2024.108538_bb0010","first-page":"13","article-title":"The prevalence of PMM2-CDG in Estonia based on population carrier frequencies and diagnosed patients","volume":"39","author":"Vals","year":"2017","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2024.108538_bb0015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ng0597-88","article-title":"Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome)","volume":"16, n.o 1","author":"Matthijs","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymgme.2024.108538_bb0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/318199","article-title":"High residual activity of PMM2 in Patients\u2019 fibroblasts: possible pitfall in the diagnosis of CDG-Ia (Phosphomannomutase deficiency)","volume":"68","author":"Gr\u00fcnewald","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2024.108538_bb0025","unstructured":"D. J. Lefeber, H. H. Freeze, R. Steet, T. Kinoshita, \u00abCongenital disorders of glycosylation\u00bb, en Essentials of Glycobiology, 4th ed., A. Varki, R. D. Cummings, J. D. Esko, P. Stanley, G. W. Hart, M. Aebi, D. Mohnen, T. Kinoshita, N. H. Packer, J. H. Prestegard, R. L. Schnaar, P. H. Seeberger, Eds., Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 2022. Accedido: 4 de enero de 2023. [En l\u00ednea]. Disponible en: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK579928\/."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108538_bb0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.18388\/abp.2013_1965","article-title":"Congenital disorders of glycosylation. Part I. Defects of protein N-glycosylation","volume":"60","author":"Cylwik","year":"2013","journal-title":"Acta Biochim. Pol."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108538_bb0035","article-title":"Tracer metabolomics reveals the role of aldose reductase in glycosylation","volume":"4","author":"Radenkovic","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"8","key":"10.1016\/j.ymgme.2024.108538_bb0040","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3390\/genes14081585","article-title":"Interplay of impaired cellular bioenergetics and autophagy in PMM2-CDG","volume":"14","author":"Ligezka","year":"2023","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.ymgme.2024.108538_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107629","article-title":"Metabolic adaptation of human skin fibroblasts to ER stress caused by glycosylation defect in PMM2-CDG","volume":"139","author":"Zdrazilova","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108538_bb0050","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s10545-015-9874-0","article-title":"Lack of phosphomannomutase 2 affects Xenopus laevis morphogenesis and the non-canonical Wnt5a\/Ror2 signalling","volume":"38","author":"Himmelreich","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"issue":"9","key":"10.1016\/j.ymgme.2024.108538_bb0055","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.bbadis.2009.01.003","article-title":"The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia)","volume":"1792","author":"Grunewald","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"issue":"11","key":"10.1016\/j.ymgme.2024.108538_bb0060","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ejmg.2017.10.012","article-title":"Congenital disorders of glycosylation (CDG): quo vadis?","volume":"61","author":"Peanne","year":"2018","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.ymgme.2024.108538_bb0065","first-page":"123","article-title":"Expanding the spectrum of PMM2-CDG phenotype","volume":"5","author":"Vuillaumier-Barrot","year":"2011","journal-title":"JIMD Rep."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108538_bb0070","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jocn.2006.04.008","article-title":"Congenital disorder of glycosylation type 1a: three siblings with a mild neurological phenotype","volume":"14","author":"Coman","year":"2007","journal-title":"J. Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108538_bb0075","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/adc.85.3.236","article-title":"Congenital disorder of glycosylation type Ia (CDG-Ia): phenotypic spectrum of the R141H\/F119L genotype","volume":"85","author":"Kjaergaard","year":"2001","journal-title":"Arch. Dis. Child."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108538_bb0080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/jmg.38.1.14","article-title":"A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases","volume":"38","author":"de Lonlay","year":"2001","journal-title":"J. Med. Genet."},{"issue":"8","key":"10.1016\/j.ymgme.2024.108538_bb0085","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1651-2227.1994.tb13166.x","article-title":"Carbohydrate-deficient glycoprotein syndrome with previously unreported features","volume":"83","author":"Eyskens","year":"1994","journal-title":"Acta Paediatr."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108538_bb0090","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ejpn.2008.09.002","article-title":"Long-term evolution of eight Spanish patients with CDG type Ia: typical and atypical manifestations","volume":"13","author":"P\u00e9rez-Due\u00f1as","year":"2009","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108538_bb0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jimd.12024","article-title":"International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: diagnosis, treatment and follow up","volume":"42","author":"Altassan","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108538_bb0100","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0009-8981(84)90059-7","article-title":"Sialic acid-deficient serum and cerebrospinal fluid transferrin in a newly recognized genetic syndrome","volume":"144","author":"Jaeken","year":"1984","journal-title":"Clin. Chim. Acta"},{"issue":"45","key":"10.1016\/j.ymgme.2024.108538_bb0105","doi-asserted-by":"crossref","first-page":"39431","DOI":"10.1074\/jbc.M111.285502","article-title":"Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts","volume":"286","author":"Sharma","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.ymgme.2024.108538_bb0110","article-title":"Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG","volume":"12","author":"Iyer","year":"2019","journal-title":"Dis. Model. Mech."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108538_bb0115","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ana.25457","article-title":"AZATAX: acetazolamide safety and efficacy in cerebellar syndrome in PMM2 congenital disorder of glycosylation (PMM2-CDG)","volume":"85","author":"Mart\u00ednez-Monseny","year":"2019","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108538_bb0120","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/humu.23138","article-title":"Pharmacological chaperoning: a potential treatment for PMM2-CDG","volume":"38","author":"Yuste-Checa","year":"2017","journal-title":"Hum. Mutat."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108538_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165777","article-title":"Proteostasis regulators as potential rescuers of PMM2 activity","volume":"1866","author":"Vilas","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.ymgme.2024.108538_bb0130","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jpeds.2016.12.060","article-title":"A population-based study on congenital disorders of protein N- and combined with O-glycosylation experience in clinical and genetic diagnosis","volume":"183","author":"P\u00e9rez-Cerd\u00e1","year":"2017","journal-title":"J. Pediatr."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108538_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41390-018-0206-6","article-title":"Ten years of screening for congenital disorders of glycosylation in Argentina: case studies and pitfalls","volume":"84","author":"Asteggiano","year":"2018","journal-title":"Pediatr. Res."},{"issue":"10","key":"10.1016\/j.ymgme.2024.108538_bb0140","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41436-021-01203-z","article-title":"Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Gregg","year":"2021","journal-title":"Genet. Med."},{"issue":"11","key":"10.1016\/j.ymgme.2024.108538_bb0145","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3390\/jpm12111781","article-title":"The Australian reproductive genetic carrier screening project (Mackenzie\u2019s Mission): design and implementation","volume":"12","author":"Archibald","year":"2022","journal-title":"J. Pers. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108538_bb0150","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jlb\/lsx038","article-title":"The known unknown: the challenges of genetic variants of uncertain significance in clinical practice","volume":"4","author":"Hoffman-Andrews","year":"2018","journal-title":"J. Law Biosci."},{"issue":"10","key":"10.1016\/j.ymgme.2024.108538_bb0155","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/humu.24431","article-title":"A functional platform for the selection of pathogenic variants of PMM2 amenable to rescue via the use of pharmacological chaperones","volume":"43","author":"Segovia-Falquina","year":"2022","journal-title":"Hum. Mutat."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108538_bb0160","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/138920006775541552","article-title":"Preclinical pharmacokinetics: an approach towards safer and efficacious drugs","volume":"7","author":"Singh","year":"2006","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ymgme.2024.108538_bb0165","doi-asserted-by":"crossref","unstructured":"A. Egesten, H. Herwald, \u00abModelers Modelling Models\u00bb, J. Innate Immun., vol. 13, n.o 2, pp. 61\u201362, mar. 2021, doi: https:\/\/doi.org\/10.1159\/000515202.","DOI":"10.1159\/000515202"},{"issue":"4","key":"10.1016\/j.ymgme.2024.108538_bb0170","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10545-011-9328-2","article-title":"Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations","volume":"34","author":"Vega","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"issue":"9","key":"10.1016\/j.ymgme.2024.108538_bb0175","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/humu.22817","article-title":"The effects of PMM2-CDG-causing mutations on the folding, activity, and stability of the PMM2 protein","volume":"36","author":"Yuste-Checa","year":"2015","journal-title":"Hum. Mutat."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108538_bb0180","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1074\/mcp.M115.054122","article-title":"Glycomic characterization of induced pluripotent stem cells derived from a patient suffering from Phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG)","volume":"15","author":"Thiesler","year":"2016","journal-title":"Mol. Cell. Proteomics"},{"issue":"2","key":"10.1016\/j.ymgme.2024.108538_bb0185","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/jimd.12461","article-title":"Insight on molecular pathogenesis and pharmacochaperoning potential in phosphomannomutase 2 deficiency, provided by novel human phosphomannomutase 2 structures","volume":"45","author":"Briso-Montiano","year":"2022","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108538_bb0190","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ymgme.2021.11.002","article-title":"Assessing the effects of PMM2 variants on protein stability","volume":"134","author":"Quelhas","year":"2021","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108538_bb0195","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1128\/MCB.02391-05","article-title":"Targeted disruption of the mouse phosphomannomutase 2 gene causes early embryonic lethality","volume":"265","author":"Thiel","year":"2006","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108538_bb0200","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nm.2548","article-title":"Successful prenatal mannose treatment for congenital disorder of glycosylation-Ia in mice","volume":"18","author":"Schneider","year":"2011","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108538_bb0205","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1242\/dmm.022939","article-title":"Synaptic roles for phosphomannomutase type 2 in a new Drosophila congenital disorder of glycosylation disease model","volume":"9","author":"Parkinson","year":"2016","journal-title":"Dis. Model. Mech."},{"issue":"21","key":"10.1016\/j.ymgme.2024.108538_bb0210","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1091\/mbc.e12-05-0411","article-title":"A zebrafish model of PMM2-CDG reveals altered neurogenesis and a substrate-accumulation mechanism for N-linked glycosylation deficiency","volume":"23","author":"Cline","year":"2012","journal-title":"Mol. Biol. Cell"},{"issue":"11","key":"10.1016\/j.ymgme.2024.108538_bb0215","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1073\/pnas.1714056115","article-title":"Nrf2 activation attenuates genetic endoplasmic reticulum stress induced by a mutation in the phosphomannomutase 2 gene in zebrafish","volume":"115","author":"Mukaigasa","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.ymgme.2024.108538_bb0220","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1093\/hmg\/ddw085","article-title":"A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2","volume":"25","author":"Chan","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2024.108538_bb0225","doi-asserted-by":"crossref","unstructured":"E. J. Klaver et al., \u00abProtease-dependent defects in N-cadherin processing drive PMM2-CDG pathogenesis\u00bb, JCI Insight, 6, 24, e153474, doi: https:\/\/doi.org\/10.1172\/jci.insight.153474.","DOI":"10.1172\/jci.insight.153474"},{"issue":"2","key":"10.1016\/j.ymgme.2024.108538_bb0230","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1369\/0022155414562646","article-title":"Expression of human skin-specific genes defined by transcriptomics and antibody-based profiling","volume":"63","author":"Edqvist","year":"2015","journal-title":"J. Histochem. Cytochem."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108538_bb0235","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/0014-4827(65)90211-9","article-title":"The limited in vitro lifetime of human diploid cell strains","volume":"37","author":"Hayflick","year":"1965","journal-title":"Exp. Cell Res."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108538_bb0240","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1152\/physrev.1993.73.3.617","article-title":"Replicative senescence of human fibroblast-like cells in culture","volume":"73","author":"Cristofalo","year":"1993","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ymgme.2024.108538_bb0245","doi-asserted-by":"crossref","unstructured":"S. Akiyama, \u00ab[4] HeLa cell lines\u00bb, en Methods in Enzymology, 151, Academic Press, 1987, 38\u201350. doi: https:\/\/doi.org\/10.1016\/S0076-6879(87)51007-2.","DOI":"10.1016\/S0076-6879(87)51007-2"},{"key":"10.1016\/j.ymgme.2024.108538_bb0250","doi-asserted-by":"crossref","unstructured":"M. T. Donato, R. Jover, y M. J. G\u00f3mez-Lech\u00f3n, \u00abHepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering\u00bb, Curr. Drug Metab., 14, 9, 946\u2013968.","DOI":"10.2174\/1389200211314090002"},{"issue":"8","key":"10.1016\/j.ymgme.2024.108538_bb0255","first-page":"1086","article-title":"SH-SY5Y human neuroblastoma cell line:in vitrocell model of dopaminergic neurons in Parkinson\u2019s disease","volume":"123","author":"Xie","year":"2010","journal-title":"Chin. Med. J."},{"issue":"10","key":"10.1016\/j.ymgme.2024.108538_bb0260","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/cbin.10137","article-title":"Immortality of cell lines: challenges and advantages of establishment","volume":"37","author":"Irfan Maqsood","year":"2013","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ymgme.2024.108538_bb0265","article-title":"Differentiation of the SH-SY5Y human neuroblastoma cell line","volume":"108","author":"Shipley","year":"2016","journal-title":"J. Vis. Exp."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108538_bb0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nbt.2507","article-title":"Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease","volume":"31","author":"Cho","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.ymgme.2024.108538_bb0275","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"issue":"12","key":"10.1016\/j.ymgme.2024.108538_bb0280","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","article-title":"DNA sequencing with chain-terminating inhibitors","volume":"74","author":"Sanger","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.ymgme.2024.108538_bb0285","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/0014-5793(95)01357-1","article-title":"Phosphomannomutase deficiency is a cause of carbohydrate-deficient glycoprotein syndrome type I","volume":"377","author":"Van Schaftingen","year":"1995","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108538_bb0290","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1006\/bbrc.1998.8385","article-title":"A novel disorder of N-glycosylation due to phosphomannose isomerase deficiency","volume":"245","author":"de Koning","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108538_bb0295","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jcb.24316","article-title":"Oxidative stress and apoptosis in homocystinuria patients with genetic remethylation defects","volume":"114","author":"Richard","year":"2013","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ymgme.2024.108538_bb0300","article-title":"AAV9-based PMM2 gene replacement augments PMM2 expression and improves glycosylation in primary fibroblasts of patients with phosphomannomutase 2 deficiency (PMM2-CDG)","volume":"38","author":"Zhong","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108538_bb0305","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1086\/301763","article-title":"Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome type 1A","volume":"62","author":"Matthijs","year":"1998","journal-title":"Am. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108538_bb0310","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.ejhg.5200470","article-title":"Lack of hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia)","volume":"8","author":"Schollen","year":"2000","journal-title":"Eur. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108538_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2024.167163","article-title":"Transcriptomic analysis identifies dysregulated pathways and therapeutic targets in PMM2-CDG","volume":"1870","author":"Gallego","year":"2024","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"key":"10.1016\/j.ymgme.2024.108538_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2024.112160","article-title":"PMM2 controls ER\u03b1 levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells","volume":"584","author":"Cipolletti","year":"2024","journal-title":"Mol. Cell. Endocrinol."},{"issue":"22","key":"10.1016\/j.ymgme.2024.108538_bb0325","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.3390\/cells11223548","article-title":"Exploring dynamic metabolome of the HepG2 cell line: rise and fall","volume":"11","author":"Kiseleva","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ymgme.2024.108538_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107610","article-title":"Complex metabolic disharmony in PMM2-CDG paves the way to new therapeutic approaches","volume":"139","author":"Himmelreich","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108538_bb0335","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94343-w","article-title":"Gene expression analysis method integration and co-expression module detection applied to rare glucide metabolism disorders using ExpHunterSuite","volume":"11","author":"Jabato","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgme.2024.108538_bb0340","first-page":"1","article-title":"Identification of potential inhibitors against pathogenic missense mutations of PMM2 using a structure-based virtual screening approach","author":"Thirumal Kumar","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"17","key":"10.1016\/j.ymgme.2024.108538_bb0345","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/ijms20174164","article-title":"\u03b2-Glucose-1,6-bisphosphate stabilizes pathological Phophomannomutase2 mutants in vitro and represents a Lead compound to develop pharmacological chaperones for the Most common disorder of glycosylation, PMM2-CDG","volume":"20","author":"Monticelli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2024.108538_bb0350","article-title":"Yeast models of phosphomannomutase 2 deficiency, a congenital disorder of glycosylation","author":"Lao","year":"2018","journal-title":"G3"},{"issue":"10","key":"10.1016\/j.ymgme.2024.108538_bb0355","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.chembiol.2018.07.005","article-title":"Editing N-glycan site occupancy with small-molecule oligosaccharyltransferase inhibitors","volume":"25","author":"Rinis","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ymgme.2024.108538_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108487","article-title":"Liposome-encapsulated mannose-1-phosphate therapy improves global N-glycosylation in different congenital disorders of glycosylation","volume":"142","author":"Budhraja","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108538_bb0365","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jare.2023.09.002","article-title":"Plasma glycoproteomics delivers high-specificity disease biomarkers by detecting site-specific glycosylation abnormalities","volume":"61","author":"Wessels","year":"2024","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.ymgme.2024.108538_bb0370","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jcmgh.2021.09.013","article-title":"Defective lipid droplet-lysosome interaction causes fatty liver disease as evidenced by human mutations in TMEM199 and CCDC115","volume":"13","author":"Larsen","year":"2022","journal-title":"Cell. Mol. Gastroenterol. Hepatol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T02:19:56Z","timestamp":1742437196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719224004220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":74,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1096719224004220"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108538","relation":{},"ISSN":["1096-7192"],"issn-type":[{"type":"print","value":"1096-7192"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HepG2 PMM2-CDG knockout model: A versatile platform for variant and therapeutic evaluation","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Universidad Aut\u00f3noma de Madrid. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108538"}}